Hepatocellular Carcinoma Drugs - Market Opportunities and Forecast | Technavio

Technavio has published a new report on the global hepatocellular carcinoma drugs market from 2017-2021. (Graphic: Business Wire)

LONDON--()--According to the latest market study released by Technavio, the global hepatocellular carcinoma (HCC) drugs market is expected to grow at a CAGR of more than 3% during the forecast period.

This research report titled ‘Global Hepatocellular Carcinoma Drugs Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This report also includes an up to date analysis and forecasts for various market segments and all geographical regions.

According to Sapna Jha, a lead analyst at Technavio for oncology research, “Lifestyle diseases such as diabetes, obesity, and high blood pressure have a huge effect on the liver and are some of the major causes of HCC. Rising cases of HCC across the globe due to changes in lifestyle will lead to higher demand for HCC drugs.”

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

The market research analysis categorizes the global HCC drugs market into three major product segments. They are:

  • Chemotherapy
  • Brachytherapy
  • Ablation therapy

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.


Chemotherapy is a major type of cancer treatment which consists of using a single medication or a combination of more than one medication. The treatment is done with the aim to slow down or stop the growth of cancer cells. Chemotherapy is a systematic treatment, which attacks the rapidly growing cancer cells but as a side effect may even affect the healthy cells of the body. Chemotherapy is generally targeted to lower the number of cancerous cells in the body, reduce the chances of spread of cancer, and shrink the size of the tumor. Chemotherapy holds the major segment in the market owing to the major drugs of the market falling under the segment. NEXAVAR and STIVARGA are the approved drugs for HCC treatment.


This is a form of radiotherapy used for the treatment of cancers. In this process, a sealed radiation source is placed inside or around the area requiring treatment. This may be suggested by the doctor in case surgery is not possible. Doctors release tiny radioactive beads into the liver. These beads further deliver a high dose of radiation and block the blood supply to the affected area.

“Several clinical trials have been performed to use brachytherapy on liver cancer patients. As per the study published by National Institute of Health, the therapy has shown high potential and may emerge as one of the major forms of non-surgical treatment of liver cancer during the coming times,” says Sapna.

Ablation therapy

In the early stage of HCC, patients do not need to go for surgical intervention, rather, doctors prefer to go for minimally invasive procedure 'ablation' which is cost effective and has fewer side effects. Radiofrequency ablation remains the first choice amongst doctors for patients with few small size tumors.

The other preferred ablation therapy remains percutaneous ethanol injection and percutaneous acetic acid injection. Typically, patients undergoing ablation therapy are not required to stay in the hospital, which makes it a more cost-effective treatment and hence adds to its popularity.

The top vendors highlighted by Technavio’s market research analysts in this report are:

  • Bayer
  • Eli Lilly
  • Johnson and Johnson
  • Pfizer

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

According to the market study released by Technavio, the global hepatocellular carcinoma drugs market is set to grow at a CAGR of over 3% until 2021.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200